MARKET

SNY

SNY

Sanofi FR
NASDAQ
49.00
-1.36
-2.70%
After Hours: 49.00 0 0.00% 16:01 05/23 EDT
OPEN
49.50
PREV CLOSE
50.36
HIGH
49.61
LOW
48.58
VOLUME
2.78M
TURNOVER
0
52 WEEK HIGH
55.72
52 WEEK LOW
40.90
MARKET CAP
122.47B
P/E (TTM)
31.08
1D
5D
1M
3M
1Y
5Y
UPDATE 3-Zantac not a cause of woman’s cancer, jury says in first trial over drug
Jury rejects Illinois woman's claim that Zantac caused her colon cancer, jury says in first trial over drug. Thousands of lawsuits say the drug turns into a cancer-causing substance. The drugmakers say the verdict is consistent with scientific evidence. The trial is the first out of thousands of lawsuits making similar allegations.
Reuters · 8h ago
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
A second human case of bird flu confirmed in a dairy worker in Michigan. The virus has been found in dairy cattle in several states. The risk to people remains low, officials say. The spread of birdflu in dairy cows reflects an expansion of the range of mammals that can be infected.
Reuters · 1d ago
Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results
Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results. The company says the results support advancing the BTK inhibitor into phase 3. Sanofi says the drug led to a decline in loss of asthma control events compared to placebo.
Seeking Alpha · 1d ago
Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was Well-Tolerated With No New Safety Signals Observed; Results Support The Further Development And Advancement Into A Phase 3 Program
Benzinga · 1d ago
Shah Capital Ends Proxy Fight at Novavax After Sanofi Deal Boost
TipRanks · 1d ago
3 Things You Need to Know If You Buy Novavax Today
Novavax's vaccine maker's recovery story is looking brighter. The biotech company's recent deal with Sanofi could supercharge its revenue growth. Novavax has been struggling to compete in the coronavirus vaccine market. But the company is making progress and has a powerful partner in Sanofi.
The Motley Fool · 1d ago
Novavax top investor ends proxy fight after Sanofi deal
Seeking Alpha · 2d ago
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
NASDAQ · 2d ago
More
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.